Merck Serono pipeline Audited

Neurodegenerative diseases

ONO-4641 (ceralifimod, oral S1P receptor modulator)

Multiple sclerosis

Phase II

Plovamer acetate (PI-2301, second-generation peptide copolymer)

Multiple sclerosis

Phase II

ATX-MS-1467 (immune-tolerizing agent)

Multiple sclerosis

Phase I

Oncology

Erbitux® (cetuximab, anti-EGFR mAb)

Head and neck cancer

Filed in China

TH-302 (hypoxia-targeted drug)

Soft tissue sarcoma

Phase III

TH-302 (hypoxia-targeted drug)

Pancreatic cancer

Phase III

TH-302 (hypoxia-targeted drug)

Hematological malignancies and solid tumors

Phase I

DI17E6 (Anti-integrin mAb)

Colorectal cancer

Phase II

DI17E6 (Anti-integrin mAb)

Castration-resistant prostate cancer

Phase II

Pimasertib (MEK inhibitor)/gemcitabine combination

Pancreatic cancer

Phase II

Pimasertib (MEK inhibitor)

Malignant melanoma

Phase II

Pimasertib/PI3K inhibitor novel combination

Low grade ovarian cancer

Phase II¹

Pimasertib/PI3K inhibitor novel combination

Solid tumors

Phase I¹

Pimasertib/hDM2 inhibitor combination

Solid tumors

Phase I²

C-Met kinase inhibitor

Solid tumors

Phase I

Sym004 (anti-EGRF mAb mixture)

Head and neck cancer

Phase II

Sym004 (anti-EGRF mAb mixture)

Solid tumors

Phase I

P7056K and Akt inhibitor

Solid tumors

Phase I

Immuno-Oncology

NHS-IL2 (cancer immunotherapy)

Solid tumors

Phase I

NHS-IL12 (cancer immunotherapy)

Solid tumors

Phase I³

Anti-PD-L1 mAb

Solid tumors

Phase I

Tecemotide (L-BLP25, MUC1-antigen-specific cancer immunotherapy)

Non-small cell lung cancer

Phase III⁴

Immunology

Atacicept (anti-Blys/anti-APRIL fusion protein)

Systemic lupus erythematosus

Phase II⁵

Sprifermin (FGF-18)

Osteoarthritis

Phase II⁶

Endocrinology

Kuvan® (sapropterin dihydrochloride)

PKU in pediatric patients < 4 years

Phase III⁷